Skip to content
Evigrade
ModerateVitamin K antagonist anticoagulants×Antineoplastic, oral prodrug of 5-FU

Updated · Methodology

Mechanism

Acenocoumarol is a coumarin derivative and vitamin K antagonist. Liver enzymes, mainly CYP2C9, metabolise it. According to the Spanish generic acenocoumarol summary of product characteristics (SmPC), CYP2C9 inhibitors can potentiate its anticoagulant effect (acenocoumarol SmPCs, Spanish Agency of Medicines and Medical Devices, AEMPS). In a study in patients with cancer, capecitabine raised the area under the concentration curve of S-warfarin by 57% after a single 20 mg dose of warfarin. It raised the maximum international normalised ratio (INR) by 91% and did not change R-warfarin metabolism. These results indicate that capecitabine inhibits CYP2C9 and has no effect on CYP1A2 or CYP3A4 (capecitabine SmPC, European Medicines Agency, EMA; capecitabine prescribing information, US Food and Drug Administration, FDA). Altered coagulation parameters and bleeding have been reported when capecitabine was combined with coumarin anticoagulants such as warfarin and phenprocoumon. The US label reports them with vitamin K antagonists, including deaths (capecitabine SmPC, EMA; prescribing information, FDA). The documents contain no study with acenocoumarol, but it belongs to both classes named (acenocoumarol SmPC, AEMPS).

Symptoms

The main risk is bleeding. In patients on a stable dose of a vitamin K antagonist, clinically significant rises in the prothrombin time and the international normalised ratio (INR) have been reported after capecitabine was started. They appeared within several days to several months, and in a few cases within a month after capecitabine was stopped. They were seen in patients with and without liver metastases (capecitabine summary of product characteristics, SmPC, European Medicines Agency, EMA; capecitabine prescribing information, US Food and Drug Administration, FDA). With excess acenocoumarol, the most frequent signs are bleeding into the skin and blood in the urine. Other signs include bruising, gastrointestinal bleeding, vomiting blood, uterine bleeding, nosebleeds, bleeding gums and bleeding into joints (acenocoumarol SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). Cancer is one of the risk factors for bleeding during acenocoumarol treatment (acenocoumarol SmPC, AEMPS). Capecitabine itself can cause thrombocytopenia and gastrointestinal bleeding (capecitabine SmPC, EMA).

Management

The combination is not contraindicated but needs frequent coagulation monitoring. When a coumarin anticoagulant is taken with capecitabine, monitor the anticoagulant response closely with the international normalised ratio (INR) or prothrombin time and adjust the anticoagulant dose (capecitabine summary of product characteristics, SmPC, European Medicines Agency, EMA). According to the US label, check the INR more often and adjust the vitamin K antagonist dose as needed, both during capecitabine treatment and after it is stopped (capecitabine prescribing information, US Food and Drug Administration, FDA). The acenocoumarol SmPC asks for close and frequent coagulation checks, for example twice a week. This applies both when another drug is added and when it is stopped (acenocoumarol SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). A change in the acenocoumarol dose does not show in the prothrombin time for at least 36 hours. In patients outside the target range, the effect of a dose change is usually assessed after 7–8 days. Base dose adjustments on the total weekly dose, spread as evenly as possible over seven days (acenocoumarol SmPC, AEMPS). Acenocoumarol is contraindicated with a platelet count below 50×10⁹/L (acenocoumarol SmPC, AEMPS). Capecitabine is contraindicated in severe thrombocytopenia (capecitabine SmPC, EMA). The US capecitabine label asks for a complete blood count at baseline and before each cycle (FDA). With an INR of 4.5–10 and no significant bleeding, interrupt acenocoumarol. With an INR above 10, also give 1–5 mg of vitamin K1 by mouth. In significant bleeding, interrupt acenocoumarol and give 5–10 mg of vitamin K1 intravenously very slowly, no faster than 1 mg per minute (acenocoumarol SmPC, AEMPS).

Your whole list in one report

Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email

Add more drugs

Medicine list: everything you take in one place →

Sources

Other interactions with Acenocoumarol

Other interactions with Capecitabine